Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Feb;68(2):153-60.
doi: 10.1093/gerona/gls138. Epub 2012 May 4.

Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation

Affiliations
Randomized Controlled Trial

Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation

Shehzad Basaria et al. J Gerontol A Biol Sci Med Sci. 2013 Feb.

Abstract

Background: Testosterone in Older Men with Mobility Limitations Trial found an increased incidence of cardiovascular events in men randomized to testosterone, resulting in enrollment cessation by trial's Data and Safety Monitoring Board. We evaluated changes in gonadal hormones and markers of inflammation and coagulation to elucidate risk factors associated with cardiovascular events.

Methods: Men aged 65 years or more, with mobility limitation, total testosterone 100-350 ng/dL, or free testosterone less than 50 pg/mL, were randomized to placebo or 10 g testosterone gel daily for 6 months. Changes in total and free testosterone, estradiol and estrone, C-reactive protein, interleukin 6, fibrinogen, plasminogen activator inhibitor-1, and pro-brain naturetic peptide were compared between groups and within the testosterone group between subjects who experienced cardiovascular events and those who did not.

Results: Of 209 men randomized (mean age 74 years), gonadal hormones and biomarkers were available in 179 men. Baseline body mass index, gonadal hormones, lipids, Framingham risk scores, and other biomarkers were similar in the two treatment groups. Within the testosterone group, the 6-month increase in free testosterone was significantly greater in men who experienced cardiovascular events than in those who did not [mean (95% confidence interval), 10.6 (4.6-16.7) vs 5.2 (3.0-7.5) ng/dL, p = .05]. In multivariable logistic regression analysis, the change in the serum levels of free testosterone was associated with cardiovascular events.

Conclusion: Mobility-limited older men who experienced cardiovascular events had greater increases in serum free testosterone levels than those who did not.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Changes in serum levels of sex hormones from baseline to 6 months. The change in each parameter is compared between the treatment groups and within the testosterone group based on cardiovascular disease events. E1 = Estrone; E2 = Estradiol; FT = Free Testosterone; TT = Total Testosterone.

Similar articles

Cited by

References

    1. LeBrasseur NK, Lajevardi N, Miciek R, et al. Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): design and methods. Contemp Clin Trials. 2009;30:133–140. - PMC - PubMed
    1. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–122. - PMC - PubMed
    1. The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA. 1970;214:1303–1313. - PubMed
    1. Hedlund PO, Johansson R, Damber JE, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol. 2011;45:346–353. - PubMed
    1. Ridker PM, Cannon CP, Morrow D, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28. - PubMed

Publication types